Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcome drug resistance in myeloid leukemia

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA-97239; Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR, USA-97239; Department of Biochemistry and Genetics and Center for Applied Medical Research (CIMA), University of Navarra, Pio XII-55 Pamplona, Spain-31008; Howard Hughes Medical Institute, Portland, OR, USA-97239; Oncotide Pharmaceuticals, Research Triangle Park, Durham NC, USA-27710; Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR, USA-97239; Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR, USA-97239; Duke University Medical Center, Durham, NC, USA-27709.